作者
Martina Maggi, Valeria Panebianco, Augusto Mosca, Stefano Salciccia, Alessandro Gentilucci, Giovanni Di Pierro, Gian Maria Busetto, Giovanni Barchetti, Riccardo Campa, Isabella Sperduti, Francesco Del Giudice, Alessandro Sciarra
发表日期
2020/5/15
来源
European urology focus
卷号
6
期号
3
页码范围
463-478
出版商
Elsevier
简介
Context
The Prostate Imaging Reporting and Data System (PI-RADS) 3 score represents a “grey zone” that need to be further investigated to solve the issue of whether to biopsy these equivocal cases or not.
Objective
To critically analyze the current evidence on PI-RADS 3 cases. We evaluated the prevalence of PI-RADS 3 cases in the literature and detection rate of prostate cancer (PC) and clinically significant PC (csPC) at biopsy with regard to factors determining these rates.
Evidence acquisition
We searched in the Medline and Cochrane Library database from the literature from January 2009 to January 2019, following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines.
Evidence synthesis
A total of 28 studies were included in our analysis (total number of PI-RADS 3 cases: 1759, range 20–187). The prevalence of PI-RADS 3 cases reported in available studies was 17.3 …
学术搜索中的文章
M Maggi, V Panebianco, A Mosca, S Salciccia… - European urology focus, 2020